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OBJECTIVES: The aim of this study is to analyze the GPs’ routine of redirection. We 
reveals which diagnoses induce the most frequent redirection cases to specialists, which 
specialties are the most frequently targeted and how the distance from the nearest 
outpatient unit inﬂ uences the GPs’ practice. METHODS: The analysis is based on the 
monthly reports (B300 form of the Hungarian Naional Health Insurance Fund Admin-
istration (OEP) of 701 general practitioners. Study covers the years 2008 and 2009, 
14 million visits of 952 thousand inhabitants of South-Transdanubian Region of 
Hungary. GPs’ redirection routine is measured by the redirection rate, which shows 
the number of redirections related to the number of GP visits (%). RESULTS: The 
population of the region decreased by 0.8% over the years 2008–2009, however the 
number of GP visits increased by 12%. The surplus is mainly due to the H1N1 vac-
cination campaign and the rise of cardiovascular diseases and respiratory diseases of 
allergic origin. The average redirection rate was 10%. 76% of the GPs’ surgeries are 
located not farther than 15 km from the nearest outpatient unit, and 62% not farther 
than 15 km from a hospital. The distance from the nearest outpatient unit inﬂ uences 
the redirection rate, but this impact is not determining. The most frequently needed 
specialties are rheumatology, cardiology, pulmonology and orthopedics. GPs direct 
their patients of 0–14 years to specialists more rarely than patients of 15 years or 
above and also the referred diagnoses vary between the two age groups. CONCLU-
SIONS: The redirection rate is lower on case of young patients and higher on case of 
adult, and elderly patients. While young patients get to specialists mainly due to acute 
and chronic respiratory diseases (many of them have allergic origin), orthopaedic 
malformations or simply health monitoring, adult patients have cardiovascular, rheu-
matic, and endocrine problems.
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OBJECTIVES: To evaluate the preparedness of the community pharmacists in the 
State of Penang in six main management functions: Accounting, ﬁ nance, human 
resource management, marketing management, planning, and directing. METHODS: 
A cross-sectional study design was carried out with a total of 100 community phar-
macists practicing in the State of Penang, Malaysia. a pre-validated questionnaire, 
containing 3 sections was used as data collection tool. All data was analyzed using 
SPSS for Windows version 13.0. Inferential statistics were used whenever appropriate 
at alpha value of 0.05 or less considered signiﬁ cant. RESULTS: A total of 50 phar-
macists successfully responded to the survey. When respondents were asked about the 
percentage of time spent in actual management functions, 42% of them responded 
that their time is being spent on actual management functions. More than 60% of 
community pharmacists said that most of the time, they undertake tasks in accounting, 
ﬁ nance, human resource management, marketing management, planning, and direct-
ing. When respondents were compared in terms of their demographics, the time 
overseas graduates showed better preparation and performance of management func-
tions compared to local graduates. CONCLUSIONS: The ﬁ ndings of this study 
showed that most of the community pharmacists understand and undertake the 
management functions in running their community pharmacy business. Furthermore 
the ﬁ ndings suggested that local pharmacy graduates were less prepared to undertake 
various management functions compared to their overseas graduated counterparts.
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OBJECTIVES: Unplanned hospital readmissions of elderly people present an increas-
ing burden for health systems. This could be, theoretically, reduced by adequate 
preventive interventions. However, there is uncertainty about the effectiveness of dif-
ferent types of interventions. The objective of this systematic review was to summarise 
available evidence on the effectiveness of interventions to reduce the risk of unplanned 
readmissions in patients of 75 years and older and to determine the role of home care 
components. METHODS: We searched studies in MEDLINE, CINAHL, CENTRAL 
and seven other electronic databases up to October 2007 and updated the search in 
MEDLINE up to October 2009. Clinical trials (randomized or controlled) evaluating 
the effectiveness of an intervention to reduce readmissions in elderly patients compared 
to a control group were selected. Quality was assessed by the SIGN tool. The extracted 
information was presented in text and tables. RESULTS: Thirty-two clinical trials 
were included and divided into two groups: in-hospital interventions (17 studies) and 
interventions with home follow-up (15 studies). Three studies from the ﬁ rst group and 
seven from the second group found positive effects of the evaluated intervention on 
readmission outcome. CONCLUSIONS: Most of the evaluated interventions did not 
have any effect on readmissions of elderly patients. However, those interventions that 
comprised some kind of home care seem to be more likely to reduce readmissions in 
the elderly. 
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OBJECTIVES: This study aims to calculate the impact of orphan drugs on the Belgian 
drug budget in 2008 and to forecast its impact over the following ﬁ ve years. 
METHODS: The 2008 budget impact was calculated by triangulating information 
derived from multiple Belgian data sources, including Ministerial Decrees, ﬁ gures 
published by the National Institute for Health and Disability Insurance, and reim-
bursement ﬁ les submitted to the Drug Reimbursement Committee. The 2008–2013 
budget impact analysis was based on three scenarios reﬂ ecting different levels of 
growth in the number of registered orphan drugs in the European Union, the number 
of drugs reimbursed in Belgium, and the average annual cost per patient per drug in 
Belgium. The price year was 2008. RESULTS: At the end of 2008, 31 different orphan 
drugs were approved for reimbursement in Belgium for 35 different indications. The 
annual number of Belgian patients treated varied between 1 and 1080 patients per 
orphan drug. The cost per patient per year ranged from c4600 to c411,000 between 
orphan drugs. The orphan drug budget impact amounted to c66.2 million (or 5% of 
the Belgian hospital drug budget) in 2008. The impact would increase to c130–c204 
million in 2013, depending on the scenario. CONCLUSIONS: The analysis showed 
that the budget impact of orphan drugs in Belgium is substantial and rising, thereby 
putting pressure on total drug expenditure. This static analysis measured orphan drug 
costs only, assuming that other components of health expenditure do not change over 
time. Policy options to address the rising budget impact include pricing linked to return 
on investment, risk-sharing arrangements and re-appraisal of orphan drug status if 
additional indications are approved.
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OBJECTIVES: This study aims to investigate the relationship between the market 
share of generic medicines and the medicine price level in European off-patent phar-
maceutical markets. METHODS: Data on medicine volumes and on medicine values 
for a basket of 35 active substances were derived from IMS Health. Ex-manufacturer 
medicine prices were calculated by dividing market value by market volume. The 
analysis was limited to medicines in immediate-release, oral, solid dosage forms. The 
included countries were Austria, Belgium, Denmark, Germany, France, Italy, the The 
Netherlands, Spain, Sweden and the United Kingdom, which constitute a mix of 
countries with low and high generic medicines market shares. Data were available 
from June 2002 until March 2007. RESULTS: Market value has seen a substantial 
decrease in high generic market share markets (−26.6%), while the decrease in low 
market share markets was marginal (−0.06%). Market volume has risen in both high 
generic market share markets (+29.27%) and low market share markets (+27.40%) 
but the cause of rise is different for the two markets. In low generic market share 
markets, the rise was caused by the increased use of generic medicines while in high 
market share markets the rise was driven by the increased use of generic medicines 
and a shift of use from originator to generic medicines. In high generic market share 
markets, medicines prices have dropped by −43.18% and in low market share markets 
by −21.56%. CONCLUSIONS: The extent to which price competition from generic 
medicines leads to price reductions appears to vary according to the market share of 
generic medicines. High market share markets of generic medicines have seen a larger 
decrease in medicine prices than low market share markets. Countries need thus to 
create an environment which stimulates the generic medicines use and so increases the 
market share.
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OBJECTIVES: Both individuals and society stand to beneﬁ t from encouraging health 
technological innovation—individual patients through quicker access to promising 
technologies, and society through the development of a competitive life sciences sector. 
The “Innovation Pass” (UK) and the “Critical Path Initiative” (US) are 2 examples of 
current health policies aimed at promoting innovation. However, there does not seem 
to be a clear agreement on what constitutes innovation. The objective of this project 
